Today, we led the Series D financing in Olive (formerly known as CrossChx), the leading healthcare provider of robotic process automation (“RPA”) tools. Through its eponymous platform, the company streamlines repetitive, high-volume tasks by leveraging the systems and tools that its customers already have in place without complex integrations. Leveraging AI, Olive helps hospitals and health systems reduce costs, eliminate clerical error, boost efficiency, and improve satisfaction.
Our investment in Olive is the result of our thematic pursuit for solutions that help drive efficiency and lower costs using automation technology. While Olive is not unique in providing RPA solutions, we have yet to come across another company with as much proven expertise in solving challenges unique to healthcare. Sean Lane, the CEO and founder of Olive, and his team have developed a platform that delivers an immense amount of value without needing to fundamentally change the way its customers do business.
We spoke with many of Olive’s customers all of whom confirmed how integral the technology has become to their day-to-day operations. Many users referred to Olive as another member of their team, describing the work “she” did, stating they couldn’t imagine their workflow without “her.” This is the sort of thing that really underscores how Olive goes far beyond a typical software solution.
The use cases for Olive within the healthcare ecosystem are seemingly endless and we see them as only continuing to grow as the company expands with next-generation technology like Pupil, the company’s process mining solution. We look forward to partnering with the company to support growth strategies and scale the business. Alongside Ascension Ventures, Drive Capital, SVB Capital, and the other existing investors participating in this round, we at Oak HC/FT could not be more excited to partner with Sean and his team on their journey.